Table 10. mRNA Vaccine Candidates for Infectious Diseases in Phase 2 or More Advanced Clinical Trialsa.
| Vaccine name | CAS Registry Number | Disease indication | Antigen | Company |
|---|---|---|---|---|
| BNT-162b2 (B.1.1.7 + B.1.617.2) | 2883464-25-1 | COVID-19 | Prefusion stabilized S protein of SARS-CoV-2 B.1.1.7 and B.1.1.617.2 variants | BioNTech, Pfizer |
| BNT162b2 (B.1.351) | Pending | COVID-19 | Prefusion stabilized S protein of SARS-CoV-2 B.1.351 variant | BioNTech,Pfizer |
| BNT 162b2 (B.1.1.529) | Pending | COVID-19 | Prefusion stabilized S protein of SARS-CoV-2 B.1.1.529 variant | BioNTech, Pfizer |
| BNT-162b2 (WT/OMI BA.1) | Pending | COVID-19 | Prefusion stabilized S protein of SARS-CoV-2 WT and BA.1 variant | BioNTech, Pfizer |
| BNT-162b5 (WT/OMI BA.2) | Pending | COVID-19 | Prefusion stabilized S protein of SARS-CoV-2 WT and BA.2 variant | BioNTech, Pfizer |
| mRNA 1273 | Pending | COVID-19 | The full-length prefusion stabilized S protein | Moderna |
| mRNA 1273.211 | 2805221-47-8 | COVID-19 | Prefusion stabilized S protein of the SARS-CoV-2 and B.1.351 variant | Moderna |
| mRNA 1273.214 | Pending | COVID-19 | bivalent of SARS-CoV-2 spike protein from Beta and Delta variants | Moderna |
| mRNA 1273.351 | 2642373-67-7 | COVID-19 | the full-length prefusion stabilized S protein of the SARS-CoV-2 B.1.351 variant | Moderna |
| mRNA 1273.529 | 2763208-92-8 | COVID-19 | Prefusion stabilized S protein of the SARS-CoV-2 B.1.1.529 variant | Moderna |
| mRNA 1273.617 | 2882950-03-8 | COVID-19 | Prefusion stabilized S protein of the SARS-CoV-2 B.1.1.617.2 variant | Moderna |
| mRNA 1283 | 2696398-77-1 | COVID-19 | SARS-CoV-2 spike protein receptor-binding domain and N-terminal fragment | Moderna |
| mRNA 1283.529 | Pending | COVID-19 | Prefusion stabilized S protein of the SARS-CoV-2 B.1.1.529 variant | Moderna |
| mRNA 1283.211 | 2882951-80-4 | COVID-19 | Prefusion stabilized S protein of the SARS-CoV-2 B.1.351 variant | Moderna |
| LVRNA 009 | Pending | COVID-19 | SARS-CoV-2 spike protein | AIM Vaccine |
| ARCT 165 | 2714576-70-0 | COVID-19 | Self-Transcribing and Replicating mRNA encoding SARS-CoV-2 spike protein variants | Arcturus Therapeutics |
| ARCT 154 | 2698334-90-4 | COVID-19 | Self-Transcribing and Replicating mRNA encoding SARS-CoV-2 spike protein | Arcturus Therapeutics |
| ARCT 021 | 2541451-24-3 | COVID-19 | Self-Transcribing and Replicating mRNA encoding SARS-CoV-2 spike protein variants | Arcturus Therapeutics |
| BCD 250b | 2756425-11-1 | COVID-19 | The receptor-binding domain of SARS-CoV-2 spike protein | Biocad |
| COVID-19 mRNA vaccine | Pending | COVID-19 | SARS-CoV-2 spike protein | CanSino Biologics |
| SYS 6006 | Pending | COVID-19 | SARS-CoV-2 spike protein | CSPC Pharmaceutical |
| DS 5670 | 2749556-96-3 | COVID-19 | SARS-CoV-2 spike protein | Daiichi Sankyo |
| HDT 301 | 2437182-02-8 | COVID-19 | Self-amplifying RNA encoding SARS-CoV-2 spike protein | Emcure Pharmaceuticals |
| EG-COVID | Pending | COVID-19 | SARS-CoV-2 spike protein | EyeGene |
| PTX-COVID19-B | 2726459-47-6 | COVID-19 | SARS-CoV-2 spike protein | Providence Therapeutics |
| SW-BIC-213 | 2699076-70-3 | COVID-19 | The full-length SARS-CoV-2 spike protein | Stemirna Therapeutics |
| ABO1009-DP | Pending | COVID-19 | SARS-CoV-2 omicron variant spike protein | Suzhou Abogen Biosciences |
| ARCoV | 2543878-98-2 | COVID-19 | The receptor-binding domain of SARS-CoV-2 spike protein | Suzhou Abogen Biosciences |
| Awcorna | Pending | COVID-19 | SARS-CoV-2 spike protein receptor-binding domain | Walvax Biotechnology |
| Comirnaty | 2417899-77-3 | COVID-19 | The full-length prefusion stabilized S protein | BioNTech |
| Spikevax | 2430046-03-8 | COVID-19 | The full-length prefusion stabilized S protein | Moderna |
| mRNA 1073 | 2760527-92-0 | COVID-19 + influenza | Prefusion stabilized S protein of SARS-CoV-2 and hemagglutinin | Moderna |
| mRNA 1345 | 2766353-31-3 | Respiratory syncytial virus infection | RSV prefusion stabilized F glycoprotein | Moderna |
| BNT 161 | 2760529-48-2 | Influenza | Hemagglutinin from H1N1 and B/Yamagata influenza strains | BioNTech |
| mRNA 1010 | 2760527-87-3 | Influenza | Hemagglutinin from four seasonal influenza strains | Moderna |
| mRNA 1020 | 2760527-90-8 | Influenza | Hemagglutinin and neuraminidase antigens | Moderna |
| mRNA 1030 | 2760527-91-9 | Influenza | Hemagglutinin and neuraminidase antigens | Moderna |
| MRT 5407 | 2900351-99-5 | Influenza | Quadrivalent influenza vaccine | Sanofi |
| mRNA 1893 | 2882947-97-7 | Zika virus infection | Structural proteins of Zika virus | Moderna |
| mRNA 1325 | 2882946-55-4 | Zika virus infection | Structural proteins of Zika virus | Moderna |
| mRNA 1647 | 2882946-59-8 | CMV infection | Six mRNAs coding for pentamer viral antigen and glycoprotein B of CMV | Moderna |
a
Data from the CAS Content Collection, Clinicaltrials.gov, and Pharmaprojects.
b
Vaccine no longer in development.